Literature DB >> 7422708

Disposition and metabolism of adriamycin in the rat.

N Tavoloni, A M Guarino.   

Abstract

Adriamycin (ADR) is extensively excreted in bile and moderately in urine following its administration to anesthetized rats. At intravenous doses ranging from 5 to 20 mg/kg, approximately 34% of the injected ADR is excreted in bile as total drug equivalents and 6-8% in urine over a 10-hour period. Thin-layer chromatography of bile, urine and tissue extracts revealed the presence of three major metabolic products in addition to the parent drug. In either bile or urine, unchanged ADR was the predominant form excreted and accounted for about 70% of the total drug equivalents. Adriamycinol and ADR conjugates were the major metabolites, were excreted at comparable rates and together accounted for most of the remaining fluorescence or radioactivity in either body fluid. ADR itself was the main form found in all tissues examined. ADR conjugates were not detected in any tissue whereas adriamycinol was observed in kidney, heart and spleen, but not in the liver. ADR aglycones could not be detected in the heart. They appeared preferentially in the liver where, 3 h after ADR was injected, they accounted for about 40% of total tissue fluorescence or radioactivity. The low rate of ADR conversion observed in the present studies supports the hypothesis of species difference in the metabolism of the drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7422708     DOI: 10.1159/000137439

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  9 in total

1.  Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity.

Authors:  Ashley J Smuder
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-08-28       Impact factor: 3.619

Review 2.  The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio A Brito-Melo; Cayo Antônio Soares de Almeida; Lázaro Lopes Moreira; Cleiton Willian Cordeiro; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões E Silva
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

3.  Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin.

Authors:  J H Peters; G R Gordon; D Kashiwase; E M Acton
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2.

Authors:  Kazuhiko Hidemura; Ying Lan Zhao; Katsuki Ito; Akimasa Nakao; Yasuaki Tatsumi; Hiroaki Kanazawa; Kenzo Takagi; Michio Ohta; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin.

Authors:  H J Lee; W L Chiou
Journal:  Pharm Res       Date:  1989-10       Impact factor: 4.200

Review 6.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

7.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Hepatic metabolism of doxorubicin in mice and rats.

Authors:  P Vrignaud; D Londos-Gagliardi; J Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

9.  Amifostine reduces the seminiferous epithelium damage in doxorubicin-treated prepubertal rats without improving the fertility status.

Authors:  Vanessa Vendramini; Estela Sasso-Cerri; Sandra M Miraglia
Journal:  Reprod Biol Endocrinol       Date:  2010-01-10       Impact factor: 5.211

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.